BioSpace News Archive

Ibex Medical Analytics, the pioneer in artificial intelligence (AI)-powered cancer diagnostics, today announced outstanding outcomes in a clinical validation study for the first and only AI-based solution used by pathologists in routine clinical practice.

Cellero, the leading provider of donor and patient collection services, GMP-grade biomaterials, characterized immune cells, and custom research services, today announced the launch of new convalescent COVID-19 blood products to support research and vaccine development.

Sun Genomics, the direct-to-consumer personalized probiotics and gut health company, announced today the launch of Floré Defense: a custom blend of prebiotics, probiotics, and herbal supplements designed for the gut-lung microbiome axis and maintaining the body’s natural immune response to potential respiratory infection.

NOWDiagnostics, Inc. announced today that it has received Conformité Européene (CE) mark approval for its ADEXUSDx® COVID-19 antibody test for use in moderate/complex laboratory settings across 28 countries in the European Union (EU)

RapidAI, the worldwide leader in advanced imaging for stroke, today announced that Thomas Jefferson University Hospital in Philadelphia was the site of the one-millionth recorded Rapid® scan.

Elligo Health Research is proud to welcome Michael Gibertini, Ph.D. , to its leadership team. Gibertini joins the team at the healthcare-enabling company as the new chief development officer and will develop new lines of business to support Elligo’s mission to bring clinical research as a care option to patients. An industry veteran, Gibertini brings over 30 years of experience to Elligo. His unique strength moldin

RubiconMD, the leading eConsult provider, announced the launch of its new pharmacy offering, RubiconRx, designed to bridge the gap between primary care and clinical pharmacy and provide patients access to the medication support they need.

Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless cervical cancer detection test based on its patented biophotonic technology, announced today that it had submitted its protocol to FDA for a clinical study to support marketing of the LuViva® Advanced Cervical Scan in the United States. Under FDA’s Investigational Device Exemption guidelines, the Agency typically responds to companies

TScan Therapeutics, a biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies in oncology, today pre-published data on medRxiv.org identifying the precise targets of T cells isolated from COVID-19 convalescent patients. Immunodominant targets were shared among patients with the same human leukocyte antigen (HLA) type and were primarily located outside the spike protein.

Funding from Gilead will support creation of data map to systematically address the impact of the disease on Black and minority communities --